title: Bevacizumab therapy may contribute to irradiation deferral in patients with breast cancer and with central nervous system metastases: findings of a case series.
authors.affiliation: First Department of Medical Oncology, Aghios Savvas Anti-Cancer Hospital, Athens, Hellas.
authors.forename: Panteleimon
authors.initials: P
authors.lastname: Kountourakis
authors.forename: Anna
authors.initials: A
authors.lastname: Dokou
authors.forename: Eugenia
authors.initials: E
authors.lastname: Kardara
authors.forename: Serafeim
authors.initials: S
authors.lastname: Kaltsas
authors.forename: Demetrios
authors.initials: D
authors.lastname: Doufexis
authors.forename: Alexandros
authors.initials: A
authors.lastname: Tzovaras
authors.forename: Sofia
authors.initials: S
authors.lastname: Mourgela
authors.forename: Alexandros
authors.initials: A
authors.lastname: Ardavanis
mesh_terms: D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D001918:Brachytherapy / Q000379:methods*; D001932:Brain Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary* / Q000628:therapy*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab